Societal preference values for advanced melanoma health states in the United Kingdom and Australia.
BACKGROUND
No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities associated with treatment.


METHODS
Using standard gamble, utilities were elicited from 140 respondents in the United Kingdom and Australia for 13 health states.


RESULTS
Preferences decreased with reduced treatment responsiveness and with increasing toxicity.


CONCLUSIONS
These general population utilities can be incorporated into treatment-specific cost-effectiveness evaluations.
Beusterien
K M
KM
Oxford Outcomes Inc., 7315 Wisconsin Ave, 250W, Bethesda, MD 20814, USA. kathy.beusterien@oxfordoutcomes.com
Szabo
S M
SM
Kotapati
S
S
Mukherjee
J
J
Hoos
A
A
Hersey
P
P
Middleton
M R
MR
Levy
A R
AR
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001315:Australia; D003430:Cross-Sectional Studies; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D006113:United Kingdom
D000970:Antineoplastic Agents